Clinical trials: Patient-Reported Outcomes
Urologic Diseases, Patient Satisfaction
Developing a PROM for Recurrent Urinary Tract Infection
This study aims to develop and validate the first set of patient-reported outcome measures for recurrent urinary tract infection (UTI): the Recurrent UTI Symptom Scale and the Recurrent UTI Impact Questionnaire.
- Conditions
- Urologic Diseases, Patient Satisfaction, Pain, Chronic, Sexual Dysfunction
- Trial name
- NCT05086900
- Testing
- Non-interventional Cross-sectional Patient Reported Outcome Measure Development
- Where
- United Kingdom
- Volunteers
- 283 people
- Sponsor
- University of Reading
Rosacea, Erythema
Patient-Reported Outcome Of Facial Erythema (PROOF)
The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness).
- Trial name
- PROOF (NCT01885000)
- Testing
- Brimonidine tartrate was applied cutaneously once daily for 8 days., Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.
- Where
- 14 sites in Germany, Sweden and 1 more
- Volunteers
- 92 people
- Sponsor
- Galderma R&D
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
The main aim of this study is to check the disease activity in people with moderate to severe ulcerative colitis and Crohn's disease.
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- RISE-MX (NCT04873700)
- Where
- 12 sites in Mexico
- Volunteers
- 335 people
- Sponsor
- Takeda
Relapsing Multiple Sclerosis
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
- Trial name
- ARTIOS (NCT04353492)
- Testing
- Ofatumumab
- Where
- 123 sites in United States, Argentina and 25 more
- Volunteers
- 562 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer
Pembrolizumab in Elderly Patients With Advanced Lung Cancer
This is a multi-center phase II trial of intravenous (IV) Pembrolizumab MK-3475 in subjects older than 70 years with advanced Non-small cell Lung Cancer (NSCLC) expressing Programmed death-ligand 1 (PD-L1).
- Trial name
- NCT03293680
- Testing
- Pembrolizumab
- Where
- 12 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Spanish Lung Cancer Group
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 1
Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
This interventional device study aims to compare mainly standard Multiple Daily Injection (MDI) therapy vs. Accu-Chek® Solo Micropump System and investigates participant satisfaction.
- Trial name
- PRO Solo (NCT03478969)
- Testing
- Accu-Chek® Solo micropump system, mylife™ OmniPod® Insulin Management System, Multiple Daily Injections (MDI) therapy
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 181 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Eribulin in HER2 Negative Metastatic BrCa
Improvements in outcomes with metastatic breast cancer (MBC) have been observed in the last 30 years, however, overall prognosis remains poor with median survival of 2 to 3 years.
- Trial name
- NCT01827787
- Testing
- Eribulin
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- Dana-Farber Cancer Institute
Kidney Disease, End-Stage
Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney)
People living with end-stage kidney disease (ESKD) need dialysis or transplantation in order to stay alive. This illness and treatment significantly impact peoples' health, emotions, work and relationships.
- Trial name
- NCT03149328
- Testing
- Educational Support
- Where
- 2 sites in Canada
- Volunteers
- 594 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Chronic Hepatitis C, Genotype 1 or 4
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02581163
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Volunteers
- 314 people
- Sponsor
- AbbVie
Chronic Kidney Disease Requiring Chronic Dialysis
Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis
Individuals with kidney failure receiving maintenance hemodialysis (HD) have high mortality rates, driven largely by cardiovascular causes.
- Trial name
- NCT04622709
- Testing
- Furosemide (loop diuretic) Tablets
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- University of North Carolina, Chapel Hill
Multiple Sclerosis
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
Primary Objective: To describe efficacy, tolerability and convenience of teriflunomide treatment through the evaluation of Participant Reported Outcomes (PROs). Secondary Objectives: To describe disease progression using PROs.
- Trial name
- TERI-PRO (NCT01895335)
- Testing
- Teriflunomide
- Where
- 169 sites in United States, Austria and 12 more
- Volunteers
- 1,001 people
- Sponsor
- Sanofi
Heart Failure, Anemia
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in…
- Conditions
- Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction
- Trial name
- NCT00358215
- Testing
- Darbepoetin alfa
- Where
- 754 sites in United States, Argentina and 34 more
- Volunteers
- 2,278 people
- Sponsor
- Amgen